PT3204359T - Derivados de tetra-hidroisoquinolinas - Google Patents

Derivados de tetra-hidroisoquinolinas

Info

Publication number
PT3204359T
PT3204359T PT157756883T PT15775688T PT3204359T PT 3204359 T PT3204359 T PT 3204359T PT 157756883 T PT157756883 T PT 157756883T PT 15775688 T PT15775688 T PT 15775688T PT 3204359 T PT3204359 T PT 3204359T
Authority
PT
Portugal
Prior art keywords
tetrahydroisoquinoline derivatives
tetrahydroisoquinoline
derivatives
Prior art date
Application number
PT157756883T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of PT3204359T publication Critical patent/PT3204359T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
PT157756883T 2014-10-08 2015-10-06 Derivados de tetra-hidroisoquinolinas PT3204359T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14188174 2014-10-08

Publications (1)

Publication Number Publication Date
PT3204359T true PT3204359T (pt) 2020-09-24

Family

ID=51790569

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157756883T PT3204359T (pt) 2014-10-08 2015-10-06 Derivados de tetra-hidroisoquinolinas

Country Status (18)

Country Link
US (1) US10105359B2 (esLanguage)
EP (1) EP3204359B1 (esLanguage)
JP (1) JP6622299B2 (esLanguage)
CN (1) CN107001278B (esLanguage)
BR (1) BR112017007123B1 (esLanguage)
CA (1) CA2963951C (esLanguage)
CY (1) CY1123417T1 (esLanguage)
DK (1) DK3204359T3 (esLanguage)
EA (1) EA035544B1 (esLanguage)
ES (1) ES2821821T3 (esLanguage)
HR (1) HRP20201469T1 (esLanguage)
HU (1) HUE050664T2 (esLanguage)
LT (1) LT3204359T (esLanguage)
PL (1) PL3204359T3 (esLanguage)
PT (1) PT3204359T (esLanguage)
RS (1) RS60933B1 (esLanguage)
SI (1) SI3204359T1 (esLanguage)
WO (1) WO2016055479A1 (esLanguage)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11612599B2 (en) * 2016-02-25 2023-03-28 Asceneuron Sa Glycosidase inhibitors
EA036137B1 (ru) * 2016-04-13 2020-10-02 Юсб Байофарма Спрл Производные тетрагидроизохинолина
CN107698433A (zh) * 2017-09-12 2018-02-16 潍坊滨海石油化工有限公司 苯乙酸的制备方法
CA3083329A1 (en) 2017-12-01 2019-06-06 UCB Biopharma SRL Imaging agents
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
SG11202112537YA (en) * 2019-07-01 2021-12-30 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
US12358890B2 (en) * 2019-07-01 2025-07-15 UCB Biopharma SRL Substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator
JP2023522980A (ja) * 2020-04-24 2023-06-01 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Nurr1受容体調節因子及びその使用
CN111943930B (zh) * 2020-08-25 2022-11-01 南京三元阳普医药科技有限公司 Lasmiditan的合成工艺
CN116601146A (zh) * 2020-10-07 2023-08-15 伊莱利利公司 作为多巴胺d1受体正变构调节剂的苯基-3,4-二氢异喹啉-2(1h)-基-乙-1-酮衍生物
CN116507332A (zh) 2020-12-03 2023-07-28 Ucb生物制药有限责任公司 八氢异喹啉基衍生物
IL303693A (en) * 2020-12-18 2023-08-01 UCB Biopharma SRL Consequences of transformed tetrahydroisoquinoline as a positive D1 allosteric modulator
MX2023007154A (es) * 2020-12-18 2023-06-28 UCB Biopharma SRL Dispersiones solidas amorfas.
CA3202106A1 (en) 2020-12-18 2022-06-23 Adrian Hall Dihydroisoquinolinyl derivatives
US20240083925A1 (en) * 2020-12-18 2024-03-14 UCB Biopharma SRL Prodrugs of 2-(3,5-Dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone
BR112023018175A2 (pt) 2021-03-08 2023-10-31 Lilly Co Eli Uso de mevidalen e outros moduladores alostéricos d1 positivos no tratamento de alucinações e psicose relacionada à demência
EP4304577A1 (en) 2021-03-09 2024-01-17 Eli Lilly And Co. Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression
CN114671810B (zh) * 2022-03-21 2024-03-22 济南鸿湾生物技术有限公司 一种咪唑苯脲的制备方法
CN115611768B (zh) * 2022-11-14 2024-03-05 郑州大学 一种3,4-二氯苯腈的合成方法
CN118724764B (zh) * 2024-06-07 2025-11-18 绍兴文理学院 一种芳基伯磺酰胺类化合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766131A (en) * 1980-10-17 1988-08-23 Pennwalt Corporation 2-amino (or hydroxy) phenethyl-1,2,3,4-tetrahydroisoquinolines as analgesics
EA006082B1 (ru) * 2001-12-19 2005-08-25 Х. Лундбекк А/С Производные 3,4-дигидро-1h-изохинолин-2-ила
DK1749001T3 (da) * 2004-04-29 2010-06-28 Aventis Pharma Inc 3-piperidinylisochroman-5-ol som dopaminagonister
US20090099158A1 (en) 2007-03-01 2009-04-16 Grice Cheryl A Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor

Also Published As

Publication number Publication date
EA035544B1 (ru) 2020-07-03
BR112017007123A2 (pt) 2017-12-19
HUE050664T2 (hu) 2020-12-28
PL3204359T3 (pl) 2021-03-22
JP2017530185A (ja) 2017-10-12
EP3204359B1 (en) 2020-07-01
BR112017007123B1 (pt) 2023-01-31
RS60933B1 (sr) 2020-11-30
CN107001278A (zh) 2017-08-01
EA201790785A1 (ru) 2017-10-31
SI3204359T1 (sl) 2020-10-30
CN107001278B (zh) 2020-11-24
EP3204359A1 (en) 2017-08-16
CA2963951C (en) 2023-02-28
CY1123417T1 (el) 2021-12-31
JP6622299B2 (ja) 2019-12-18
DK3204359T3 (da) 2020-09-14
US10105359B2 (en) 2018-10-23
WO2016055479A1 (en) 2016-04-14
ES2821821T3 (es) 2021-04-27
CA2963951A1 (en) 2016-04-14
LT3204359T (lt) 2020-10-12
HRP20201469T1 (hr) 2020-12-11
US20170304292A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
SI3204359T1 (sl) Tetrahidroizokinolinski derivati
AU361515S (en) Dishrack
AU362944S (en) Lapboard
IL253381B (en) History of h9–pyrrolo–dipyridine
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PL3418273T3 (pl) Pochodne flawaglin
PL3233890T3 (pl) Pestiwirus
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
IL248773A0 (en) History of naphthyridinedione
IL261055A (en) Derivatives of tetrahydroisoquinoline
IL251005B (en) Pyrido-oxazinone derivatives
AP2016009530A0 (en) Cycloalkyl-linked diheterocycle derivatives
PL3097076T3 (pl) Nowe pochodne CYP-eikozanoidowe
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
GB2530305B (en) Tracers
GB201707862D0 (en) Tracers
GB201418365D0 (en) Tracers
GB201409664D0 (en) Tracers
AU5285P (en) FLOMANRER Mandevilla sanderi
AU5289P (en) FLOMANFOP Mandevilla sanderi
AU5287P (en) FLOMANPIW Mandevilla sanderi
AU5286P (en) FLOMANWHW Mandevilla sanderi
AU2014264V (en) FlatGL Templetonia retusa
GB201407585D0 (en) SMA-Inter Act
IL233408A0 (en) New Skin - Perineal